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LHONEssential hypertension (EH,MIM 145500) is themost common cardiovascular disease and affects one-quarter of
the world's adult population. Families with EH in a mode of maternal transmission have been occasionally ob-
served in clinical settings and suggested an involvement of mitochondrial DNA (mtDNA) mutation. We aimed
to characterize the role of mtDNA mutation in EH. We reported a large Han Chinese family with a maternally
inherited EH and an extraordinarily high percentage of sudden death mainly in affected females. Analysis of
the entire mtDNA genome of the proband identiﬁed a homoplasmic primary mutation m.14484T>C for Leber's
hereditary optic neuropathy (LHON), along with several variants indicating haplogroup F1 status. Intriguingly,
no maternal member in this family had LHON though they all harbored m.14484T>C. The arterial stiffness of
the members carrying mutation m.14484T>C was signiﬁcantly increased than that of non-maternal members
without thismutation. No environmental factor (including age, sex, smoking, diabetes, hyperlipidemia) was cor-
relatedwith the decreased aortic elastic properties observed in affectedmembers.Mitochondrial respiration rate
and membrane potential (ΔΨm) were signiﬁcantly reduced in lymphoblastoid cell lines established from affect-
ed members carrying m.14484T>C when compared to control cell lines (Pb0.05). There was an elevation of re-
active oxygen species and a compensatory increase of mitochondrial mass in mutant cell lines. Our results
suggest thatm.14484T>C causes EHunder certain circumstance. This study provides a paradigm for diverse phe-
notypes of the primary LHON mutation and suggests for the necessity of routine cardiac evaluation in patients
with the primary LHON mutation.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Essential hypertension (EH,MIM145500) is one of themost common
cardiovascular diseases and acts as a signiﬁcant risk factor for heart at-
tack, stroke and end-stage renal disease [1,2]. It causes a heavy global
burden and around 7.6 million people die of this disease each year [3].
Though the exact molecular pathogenesis and mode of inheritance of
EH have not been fully elucidated, genetic factor was demonstrated to
be actively involved in the onset of EH according to family and epidemi-
ologic studies [4,5]. Previous studies showed that about 35–55% of EH
cases were associated with mitochondrial dysfunction [6,7]. Clinical ob-
servation of many EH cases from families with a maternal transmission
of the disease suggested that mitochondrial DNA (mtDNA) mutationsrights reserved.might account for the onset of EH [6–8]. There are several reports for
identifying pathogenic mtDNA mutations in patients with hypertension
[9–13], but the exact mechanism has not been sufﬁciently elucidated
[14].
One clinical feature of mitochondrial disease is the complex symp-
tomcaused by the samemtDNApathogenicmutation. For instance,mu-
tation m.3243A>G could lead to a variety of human disorders such as
mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like
episodes (MELAS) and diabetes [15,16]. Many factors including mtDNA
mutation/background, nuclear genes and environmental factors were ac-
tively involved in the development of maternally inherited diseases [17].
In this study, we characterized a large Han Chinese family with ma-
ternally inherited EH and mutation m.14484T>C. We found that the
maternalmembers in this family presented no acute or subacute central
visual loss but only hypertension. We provided further experimental
evidence to show that the onset of hypertension in this familywas caused
by the LHON mutation m.14484T>C.
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A ﬁve-generation Han Chinese family (Fig. 1) with maternally
inherited EH (family EH10) was diagnosed at the Department of
Cardiology in the Calmette Hospital, Kunming Medical University.
Among the 36 subjects in this family, 10 individuals died (5 hypertensives
and 5 normotensives); living individuals included 10 maternal members
(4 hypertensives and 6 normotensives) and 16 non-maternal members
(16 normotensives). We divided all the living individuals into case
group (maternally-related members) and control group (non-maternal
members) for comparison. Physical measurements for each member
were conducted following the WHO MONICA Project standards. Individ-
uals with EH were diagnosed according to the Joint National Committee
VI criteria [18]. We sequenced the entire mtDNA genome of proband
(IV:1) using themethod described in our previous study [19] and deﬁned
the (potentially) pathogenic mutation in the matriline by a phylogenetic
approach [20]. We further quantiﬁed the heteroplasmic or homoplasmic
status of the identiﬁed pathogenic mutation in hair root, saliva and
whole blood from the proband, as well as in all maternally-related
relatives of the proband and all non-maternal individuals in this pedigree.
We established lymphoblastoid cell lines for threematernally related
(affected members III:5 and IV:1 and asymptomatic member V:1) and
three unrelated healthy individuals (C1, C2, and C3). We quantiﬁed oxy-
gen consumption rates (OCR), intracellular reactive oxygen species (ROS),
mitochondrial membrane potential (ΔΨm) and mitochondrial mass in
each cell line.
Continuous variableswere expressed asmean±SD, and discrete var-
iables in groups were expressed as frequency. Data were tested for nor-
mality using the one-sample Kolmogorov–Smirnov test (2-tailed).
Continuous variables between the two groups (maternally-related
members and non-maternal members) were analyzed by both
non-parametric (Mann–Whitney U test and two-sample Kolmogorov–
Smirnov test) and parametric (independent samples t-test) methods.
Because of the limited sample size for each group (10 versus 16),
non-parametric tests were preferred in this study. The parametric
tests were also performed as they have more statistical power for the
same number of observations under the assumption of normality or
the assumption of homogeneity of variance. The Levene's test was ap-
plied to evaluate the equality of variances. Fisher's exact test (two-tailed)
was used to compare the rates of the patient's gender, smoking and ret-
inal microvascular structural changes (RMSC). Analysis of covariance
(age, sex and BMI acting as simultaneous covariates) was used to com-
pare biochemical test values, current visual acuity, ambulatory blood
pressuremonitoring (ABPM) parameters and echocardiographic param-
eters of the maternally-related members and non-maternal members.Fig. 1. Pedigree information for a Chinese family with maternally inherited EH andm.14484T
for the complete mtDNA sequence was marked by an arrow. The age at death of each deceAll statistical analyses were performed using SPSS 13.0 (SPSS Inc., Chi-
cago, IL, USA), and Pb0.05 was considered as statistically signiﬁcant.
A detailed Methods section is available in the Online Data Supple-
ment. Written informed consents were obtained from all participants
prior to the study. This study was approved by the institutional review
boards of the Calmette Hospital and the Kunming Institute of Zoology.
3. Results
3.1. Clinical features of the family with EH
The proband (IV:1) was a 52-year-old woman and suffered from hy-
pertension at age 47. Her highest blood pressure [systolic blood pressure
(SBP)/diastolic blood pressure (DBP)] was 170/110 mm Hg in the past
5 years. The proband visited the Calmette Hospital for further clin-
ical evaluation in 2009 because of intermittent dizziness and head-
ache. After being treated by calcium channel blocker (CCB) and
angiotensin-receptor blocker, her blood pressure reduced to a normal
range (110–130/70–80 mm Hg). All clinical indexes were normal ex-
cept for ambulatory arterial stiffness index (AASI, 0.6), symmetric am-
bulatory arterial stiffness index (S-AASI, 0.4) and pulse wave velocity
(PWV, 12.9 m/s), which showed abnormal values and suggested for de-
clined aorta's compliance (Fig. 2). The echocardiogram showed E/A
ratio abnormality, which was one of the most common cardiac abnor-
malities in hypertension.
The proband had slight myopia at both eyes, and visual acuity was
0.6 in the right eye and 0.9 in the left eye. Ophthalmoscopic examina-
tion showed an abnormal pattern of chronic hypertensive retinopathy:
the arteriole-to-venule ratio of retinal vessels was reduced to 1:3 and
arteriovenous nickingwas seen at the upper temporal quadrant, despite
that both of her optic disks were normal. Examinations for intraocular
pressure, visual ﬁeld and color vision showed no sign of abnormality.
Comprehensivelymedical examination for all members in this family
showed no signs of a hearing problem, muscular diseases and neurolog-
ical disorders. Examination of electrocardiogram (ECG) and cranial mag-
netic resonance imaging (MRI) revealed no abnormality. All family
members (except for proband IV:1) did not receive any antihyper-
tensive or other cardiovascular drugs before and during their participa-
tion in this study. Measurement of aortic PWV and PP (pulse pressure)
showed an increased arterial stiffness in thematernally-related offspring
(Fig. 2 and Table S1). Nine of 17 maternal members in the pedigree
expressed hypertension and the affected male to female ratio was 1:3.5
(Fig. 1 and Table 1). Among them, ﬁve died of sudden death (stroke
and acute myocardial infarction) and the percentage of sudden death
was 100%. The mean age at onset in this family was 45.5 years (range>C. Affected individuals were marked by ﬁlled symbols. The proband that was analyzed
ased member was listed below the sample name.
Fig. 2. Imaging of MR cine phase-contrast and the velocity–time curves of ascending aorta and the abdominal aorta. The position imaging of ascending aorta (A) and abdominal
aorta (B) were measured by MR cine phase-contrast. Non-maternal member IV:8 (48 years old, male) of this family had good compliance and slow PWV (7.2 m/s) (C), whereas
the proband (IV:1) had bad compliance and fast PWV (12.9 m/s) (D). Maternal members III:5 and IV:3 of the proband all had bad compliance and fast PWV (E: III:5, 14.5 m/s;
F: IV:3, 11.0 m/s). “a”—Level of ascending aorta, which is 1.5 cm above the aortic valve; “d”—level of abdominal aorta, which is 1.5 cm above the common iliac bifurcation; “ad”
is the distance between the ascending aorta and the abdominal aorta. The beginning points of the time–speed curve of ascending aorta and abdominal aorta are marked by arrows.
Table 1
Clinical information of maternally-related members in family EH10.
Subject Gender Age at test (years) Age of onset (years) Age of death (years) BPT (SBP/DBP) (mm Hg) HCBPMR (SBP/DBP) (mm Hg) Cause of death
I:2 F – Unknown 65 – Unknown Stroke
II:1 F – – 30 – Unknown Accident
II:2 F – 50 76 – 180/90 Stroke
II:4 F – 48 64 – 180/90 Stroke
III:1 F – 40 69 – 180/110 AMI
III:3 M – 40 70 – 180/100 Stroke
III:5 F 73 45 – 160/90 170/90 –
III:7 M 69 – – 105/64 120/70 –
III:9 F – – 22 – Unknown Drowning
IV:1 F 52 47 – 120/80 170/110 –
IV:3 F 50 – – 96/60 125/70 –
IV:5 M 47 48 – 145/90 160/100 –
IV:9 F 44 46 – 135/85 156/100 –
IV:11 M 42 – – 106/64 120/68 –
V:1 F 27 – – 114/72 120/75 –
V:2 F 19 – – 100/60 110/62 –
V:4 F 24 – – 100/70 115/75 –
F: female; M: male; SBP: systolic blood pressure; DBP: diastolic blood pressure; AMI: acute myocardial infarction; HCBPMR: the highest casual blood pressure of medical record;
BPT: blood pressure of test.
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geon) had a relatively early onset of EH (both at age 40), possibly
burdened by work load and stress. The mean onset age of affected
members in generation III (41.7 years) was smaller than that of genera-
tion II (49.0 years) or IV (47.0 years); note that this estimation was
based on a very limited number of individuals (Tables 1 and S1). The
penetrance of EH in the maternally-related members was 52.9% (9/17),
and it increased to 64.3% (9/14) after we excluded younger members
in the ﬁfth generation (mean age 23.3±4.0 years).
We compared the ambulatory blood pressuremonitoring (ABPM) pa-
rameters, PWV and biochemical test values between the maternal and
non-maternal members by using both non-parametric and parametricTable 2
Clinical features of all 26 members in family EH10.
Parameter Maternal members (n=10) Non-mate
Demographic information
Age, years 44.70±17.91 49.81±16
Female (%) 7 (70) 8 (50)
Smoking (%) 4 (40) 7 (44)
BMI, kg/m2 21.59±2.54 22.45±2.1
WHR 0.79±0.09 0.82±0.07
Biochemical test values
FBS, mmol/L 4.49±0.38 4.70±0.28
TC, mmol/L 4.54±0.32 4.68±0.71
TG, mmol/L 1.18±0.23 1.51±0.72
HDL, mmol/L 1.43±0.23 1.32±0.31
LDL, mmol/L 2.53±0.47 2.90±0.79
UA, μmol/L 255.50±71.76 265.44±1
BUN, mmol/L 5.40±0.94 5.79±0.66
Cr, μmol/L 101.20±16.88 97.88±15
Optical examinations
Current visual acuity (OD) 0.72±0.40 0.67±0.40
Current visual acuity (OS) 0.78±0.33 0.69±0.35
Prevalence of RMSC, n (%) 7 (70) 5 (31)
ABPM parameters
24hSBP, mm Hg 110.30±12.07 102.75±7
24hDBP, mm Hg 64.60±4.17 68.69±6.3
24hPP, mm Hg 45.70±10.12 34.06±3.8
dSBP, mm Hg 114.70±12.24 107.88±7
dDBP, mm Hg 67.50±4.45 71.44±6.2
dPP, mm Hg 47.20±9.19 36.44±3.9
nSBP, mm Hg 102.70±11.00 96.13±6.6
nDBP, mm Hg 60.20±3.97 64.44±6.8
nPP, mm Hg 42.50±9.07 31.69±4.6
S-AASI 0.32±0.13 0.20±0.06
AASI 0.46±0.14 0.30±0.07
24hHR, bpm 76.20±7.61 74.88±10
Aorta's compliance
PWV, m/sec 10.76±1.97 7.89±1.10
Echocardiographic parameters
LVd, mm 42.30±4.40 39.88±2.0
LA, mm 32.00±6.45 28.99±2.0
IVS, mm 9.59±1.68 8.45±0.48
LVPW, mm 9.14±1.49 8.06±0.66
LVMI, g/m2 95.61±34.66 65.94±10
EF, % 64.04±2.78 63.66±2.8
E, m/s 0.90±0.09 0.93±0.13
A, m/s 0.81±0.14 0.73±0.09
E/A 1.14±0.20 1.28±0.14
BMI: body mass index; WHR: waist hip ratio; FBS: fasting blood sugar; TC: total cholesterol;
acid; BUN: blood urea nitrogen; Cr: creatine; OD: right eye; OS: left eye; RMSC: retinal mic
24 h systolic blood pressure; 24hDBP: 24 h diastolic blood pressure; 24hPP: 24 h pulse pre
pulse pressure; nSBP: night systolic blood pressure; nDBP: night diastolic blood pressure; n
ambulatory arterial stiffness index; 24hHR: 24 h heart rate; PWV: pulse wave velocity; LVd
tum thickness; LVPW: left ventricular posterior wall thickness; LVMI: left ventricular mass i
⁎ A P valueb0.05 was marked by a star.
a Independent samples t-test.
b Mann–Whitney U test and.
c Two-sample Kolmogorov–Smirnov test was used for continuous variables. For discretetests (with adjustment for age, sex and body mass index [BMI]). As
shown in Table 2 andTable S2, thematernally-relatedmembers had a sig-
niﬁcantly higher value of 24 h pulse pressure (24hPP) (Pb0.05), day
pulse pressure (dPP) (Pb0.02), night pulse pressure (nPP) (Pb0.01),
S-AASI (Pb0.02), AASI (Pb0.02) and PWV (Pb0.02) than the
non-maternal members. There was statistical difference for SBP of day-
time, nighttime and 24-hour (Pb0.05) between the two groups when
the effects of age, sex, and BMI were taken into consideration. Other fac-
tors including age, gender, smoking, BMI, waist hip ratio (WHR), fasting
blood sugar, blood lipids, uric acid, and renal function were similar be-
tween the two groups (P>0.05). Although the differences of eye vi-
sion and rate of retinal microvascular structural changes (RMSC)rnal members (n=16) P-valuea P-valueb P-valuec
.94 0.471 0.580 0.992
0.428 0.428 0.428
1.000 1.000 1.000
3 0.362 0.329 0.637
0.340 0.178 0.314
0.119 0.193 0.438
0.501 0.579 0.394
0.100 0.126 0.216
0.326 0.343 0.637
0.140 0.235 0.534
03.99 0.794 0.854 0.944
0.221 0.303 0.314
.60 0.613 0.895 0.992
0.754 0.749 0.992
0.511 0.557 0.966
0.105 0.105 0.105
.26 0.097 0.096 0.485
1 0.083 0.090 0.144
6 0.005⁎ 0.001⁎ 0.034⁎
.17 0.134 0.162 0.352
9 0.098 0.064 0.314
5 0.005⁎ 0.001⁎ 0.013⁎
5 0.111 0.107 0.352
5 0.089 0.125 0.189
3 0.004⁎ 0.001⁎ 0.007⁎
0.014⁎ 0.007⁎ 0.013⁎
0.008⁎ 0.005⁎ 0.013⁎
.00 0.723 0.833 0.992
0.001⁎ 0.001⁎ 0.016⁎
3 0.129 0.137 0.165
6 0.183 0.039⁎ 0.013⁎
0.063 0.090 0.005⁎
0.053 0.101 0.024⁎
.81 0.025⁎ 0.061 0.005⁎
1 0.741 0.654 0.999
0.467 0.561 0.836
0.139 0.154 0.485
0.069 0.178 0.278
TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; UA: urea
rovascular structural changes; ABPM: ambulatory blood pressure monitoring; 24hSBP:
ssure; dSBP: day systolic blood pressure; dDBP: day diastolic blood pressure; dPP: day
PP: night pulse pressure; S-AASI: symmetric ambulatory arterial stiffness index; AASI:
: left ventricular diastolic diameter; LA: left atrium diameter; IVS: interventricular sep-
ndex; EF: ejection fraction; E: early mitral inﬂow velocity; A: late mitral inﬂow velocity.
variables, Fisher's exact test (two-tailed) was used.
Fig. 3. Classiﬁcation tree of the proband mtDNA, four near-matched sequences from
published sources and one healthy donor. Sequences GU392087, GU392088, GU392089 and
FJ748713were fromGenBank. Healthy donor C3 (28 years old,male)was newly determined
in this study. All sequence variationswere scored relative to the revised Cambridge reference
sequence (rCRS) [21]. The order of mutations on each uninterrupted branch section is arbi-
trary. Recurrent variations are underlined; back mutations are underlined and marked by
“@”. Sufﬁx “G” refers to transversion and “+C” indicates an insertion of cytosine. Previously
conﬁrmed pathogenic mutations are in bold. The synonymous and non-synonymous
coding-region variants in each mtDNA are further denoted by “/s” and “/ns”, respec-
tively. Variations in the ribosomal RNA genes are denoted by “/r”.
1539H. Guo et al. / Biochimica et Biophysica Acta 1822 (2012) 1535–1543between the two groups were not statistically different (P>0.05),
maternally-related subjects had a higher prevalence of retinal microvas-
cular signs (Table 2). All these observations suggested that arterial struc-
tural abnormality of mother–offspring units was more severe than that
of non-mother–offspring units.
Echocardiographic parameters of all members were shown in Table
S3. The maternally-related members displayed a signiﬁcantly higher
level of left ventricular mass index (LVMI) (two-sample Kolmogorov–
Smirnov test, P=0.005; independent samples t-test, P=0.025; adjust-
ed Pb0.001) (Table 2 and Table S2) compared to non-maternal mem-
bers. Signiﬁcant differences for left ventricular diastolic diameter (LVd),
left atrium diameter (LA), interventricular septum thickness (IVS), left
ventricular posterior wall thickness (LVPW), and E/A were observed be-
tween the two groups when effects of age, sex, and BMI were con-
sidered (Pb0.05) (Table S2), suggesting hypertension and arterial
stiffness-associated cardiac remodeling.
3.2. Presence of m.14484T>C in the matriline
Analysis of the completemtDNA sequence of the proband identiﬁed a
total of 30 homoplasmic variants relative to the revised Cambridge refer-
ence sequence (rCRS) [21], in which 23 were haplogroup-characteristic
variants and suggested it belongs to haplogroup F1b'd (Fig. 3). Among
7 private variants in this matriline, four (m.309insCC, m.523–524del,
m.16183A>C and m.16519T>C) were located in the control region,
three were located in the coding region (m.2389C>T in the MT-RNR2
gene, m.3398T>C in the MT-ND1 gene, and m.14484T>C in the
MT-ND6 gene). All these private variants were previously reported and
had no potential pathogenicity except for m.14484T>C, which was one
of the well-known primary LHON mutations. Mutation m.14484T>C
was homoplasmic in hair root, saliva and whole blood from the proband
(Fig. S1). This mutation was presented in all maternally-related relatives
of the proband but was absent in all non-maternal individuals (Figs. S1
and S2). We presented a sequence variation of the proband, together
with some related mtDNAs which belonged to the same haplogroup in
a tree. Apparently, therewas no clear evidence for a synergistic effect be-
tween m.14484T>C and other private variants in this matriline, as this
mtDNA did not harbor any private variants on its terminal branch in
the tree (Fig. 3). The complete mtDNA sequences of the proband and a
healthy control (C3) belonging to haplogroup F1a1c were deposited in
GenBank under accession nos. JN133516–JN133517.
3.3. Alteration of mitochondrial function in mutant cells
To evaluate mitochondrial function of lymphoblastoid cell lines
established from three maternally-related members with m.14484T>C
and three unrelated healthy controls, we used a Clark electrode to mea-
sure oxygen consumption rate (OCR) in live cells. The mutant cell lines
exhibited signiﬁcantly lower OCR than control cell lines (Fig. 4 and
Table S7). We added different respiratory inhibitors to determine
which respiratory complex was the pronounced one being affected.
We employed ATP-coupled respiration, basal mitochondrial respiration
and maximal respiratory capacity to represent the activities of complex
V, complex I and the overall mitochondrial oxygen consumption capac-
ity dependent on the mitochondrial membrane potential, respectively.
The OCR value of each respective state was normalized to the initial
value before adding the inhibitor, whichwas arbitrarily set to 1. Surpris-
ingly, all three mitochondrial respiration parameters decreased signiﬁ-
cantly in mutant cell lines (Pb0.05) (Fig. 4B and Table S7). As maximal
respiratory capacity reﬂected the permeability of a mitochondrial outer
membrane (ΔΨm), we measured membrane potential in cell lines with
and without m.14484T>C. Concordant with the OCR result, the mean
value of ΔΨm in mutant cells decreased remarkably (up to 87.9%) com-
pared to that of control cells (Pb0.05, Fig. 5A–B and Table S7).
We further tested the alteration of reactive oxygen species (ROS)
and mitochondrial mass in cell lines with and without m.14484T>C,which are sensitive to mitochondrial dysfunction. The average ROS
level of mutant cells was higher than that of control cells (Fig. 5C–D
and Table S7), with an increase of up to 140.6%. Intriguingly, we also ob-
served an elevation of mean value of mitochondrial mass (up to 37.4%,
albeit the difference was not statistically signiﬁcant) in all mutant cell
Fig. 4.Mutation m.14484T>C affects mitochondrial respiratory functions. (A) Representative diagram of absolute oxygen consumption rates (OCR, pmol per minute per 3×106 cells) in
cell lines of a healthy control (C2) and a patient withm.14484T>C (IV:1). Vertical dashed lines indicate the time of adding the indicated drugs. (B) Different respiratory parameters in the
control cell lines (C1, C2 and C3) and cell lines with m.14484T>C (III:5, IV:1 and V:1). Rates were normalized to the oxygen consumption rate prior to the treatment of drugs, which was
arbitrarily set to 1. The bar represents mean±SD of the rates collected from three independent measurements.
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for mitochondrial dysfunction in the presence of m.14484T>C. Accord-
ingly, we observed no essential difference for an mtDNA copy number
(Fig. S3) and the overall cellular ATP levels (Fig. S4) between mutant
and control cell lines.
4. Discussion
Accumulating evidence suggested that mitochondrial damage and
dysfunction were actively involved in cardiovascular disease [22,23].
In this study, we performed the clinical, genetic, and molecular char-
acterization of a large family with maternal hereditary hypertension
and LHON mutation m.14484T>C. Clinical examination and evalua-
tion showed that the parameters related to vascular aging (includingFig. 5. Alterations in ΔΨm, intracellular ROS and mitochondrial mass. (A) Representative res
IV:1 and healthy control (C3) was analyzed by DiOC6(3) staining. R1 gates the polarized pop
and C3) and three affected members with m.14484T>C (III:5, IV:1 and V:1). Each bar represe
cells was decreased by 87.9% compared to that of the control cell lines. (C) Representative st
and patient IV:1 R1 gates the ROS positive population. Vitamin K3 (Vit-K3), which induce
160 μM Vit-K3 at 37 °C for 3 h before the ﬁnal staining. (D) Quantiﬁcation of relative ROS
m.14484T>C mutation. Bars represent mean±SD of ﬁve independent experiments. In all ex
tative diagram for quantiﬁcation of mitochondrial mass. Cell lines from IV:1 and from contro
analysis. R1 gates the positive red ﬂuorescence population. (F) Mutant cells lines had a com
are mean±SD of two independent experiments with triplicate samples. (G) Mitochondrial
and were analyzed by confocal microscopy; depicted in this ﬁgure is the original magniﬁcaPP, S-AASI, AASI and PWV) of the maternally-related members pres-
ented signiﬁcantly higher values than those of non-maternal members.
In particular, four maternally-related members died of hemorrhagic
stroke and one died of acute myocardial infarction, indicating problems
with vascular remodeling in this family. The aortic stiffness, as one of
themain causes of increased blood pressure [24], was evident in affect-
ed members (Fig. 3; Tables 2 and S1). Our observation indicated that
the primary increase in large artery stiffness caused by mutation
m.14484T>C preceded the development of hypertension [25]. However,
affected members of this family were not isolated systolic hypertension,
indicating that structural abnormality of small arteries may also play a
role in EH. More families are required to solidify our speculation.
The striking clinical feature of this family is that allmaternally-related
members had no apparent sign for LHON but EH, despite that they hadult of ﬂow cytoﬂuorometric analysis for ΔΨm quantiﬁcation. Cell lines established from
ulation. (B) The relative ΔΨm values of cell lines from three normal individuals (C1, C2
nts mean±SD of three independent measurements. The mean value of ΔΨm inmutant
aining of intracellular ROS using DCF-DA in cell lines derived from normal individual C3
d intracellular ROS increase was used as a positive control. Cells were incubated with
level in cell lines of three normal individuals and three members of the family with
periments, each cell line was cultured and analyzed in duplicated wells. (E) Represen-
l (C3) were stained by MitoTracker Red FM and were analyzed by ﬂow cytoﬂuorometric
pensatory increased mitochondrial mass compared to that of control cell lines. Results
mass of cell lines from V:1 and from control (C3) were stained by MitoTracker Red FM
tion×100.
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patients expressed cardiac or vascular abnormalities, such as
pre-excitation syndrome [26,27], myocardial thickening, left ven-
tricular noncompaction (LVNC), dilated heart [28,29], mild degener-
ative cardiomyopathy [30], high aortic stiffness indexes [31] and
intracranial arteriovenous malformation [32], there is no report for
the presence of primary LHON mutation m.14484T>C in a family with
EH but without clinical expression of LHON to date. Analyses of demo-
graphic data and biochemical test values of all available members
in this EH family suggested that no environmental factor, but heredi-
tary factor, accounted for the maternal transmission of the disease. De-
termination of the entire mtDNA genome showed that no other
pathogenic mutation, except for m.14484T>C, would account for hyper-
tension (Fig. 3). Note that this family had a non-synonymous variant
m.3398T>C, which was said to be pathogenic in previous studies
[33,34]. This variant existed in different populations worldwide and
was one of characteristic motifs for haplogroups I2a1 and M65b [35].
By comparing to four near-matched sequences from GenBank and gen-
erated in this study, we found that m.3398T>C, together with
m.2389 C>T, deﬁne a novel subhaplogroup of F1b'd in Chinese. There-
fore, variant m.3398T>C should be best categorized as a polymorphism.
Why the primary LHONmutation m.14484T>C did not cause vision loss
but hypertension in this family is a riddle. Nikoskelainen et al. [36] found
that only a few LHONmutation carrierswithmicroangiopathy ﬁnally de-
veloped optic neuropathy, this incomplete penetrance could partially ex-
plain why no LHONwas observed in this family. It should be mentioned
that the matriline of this family belonged to haplogroup F, which was
said to be a protective factor for LHON carriers with m.14484T>C [37]
and m.11778 G>A [38], and this matrilineal background may relieve
the deleterious effect of pathogenic mtDNA mutation on the eye.
Many mtDNA mutations have been reported to be associated with
hypertension or cardiovascular diseases [9–12]. One plausible explana-
tion for the pathogenicity of deleterious mtDNAmutation in hyperten-
sion is that it causes a decrease of energy production, overproduction of
ROS, metabolic imbalance, and disturbed signal transduction, which ﬁ-
nally initiated hypertension, atherosclerosis, apoptosis, and necrosis
[39]. Dysfunction of mitochondrial respiratory chain decreased electro-
chemical potential gradient and impaired ATP synthesis, which further
destroyed systolic/diastolic functions in vascular smooth muscle cell
(VSMC) [40,41]. Elevated ROS induced vascular endothelial cell (VEC)
senescence [42,43] and was involved in the development of hyperten-
sion and atherosclerosis [22,44]. We were unable to collect VSMC and
VEC from the living affected members in this family. However, by using
lymphoblastoid cell lines derived from familymembers and healthy con-
trols, we observed a reduction of respiration rate (including ATP-coupled
respiration, maximal respiratory capacity and basal mitochondrial respi-
ration) andΔΨm, and an increase of ROS level inmutant cell lines. Along
with these alterations, there was a substantial increase of mitochondrial
mass in mutant cells, which compensated cellular ATP production and
mtDNA content in the presence of m.14484T>C. All these lines of evi-
dence supported for mitochondrial defects owing to m.14484T>C. The
ROS levels in mutant cells from symptomatic patients (III:5, 47.44% and
IV:1, 26.95%) and the asymptomatic patient (V:1, 23.40%) were substan-
tially increased compared to those of control cells (C1, 17.82%; C2, 14.99%;
C3, 7.83%).We speculated that an increase of ROS generation and a loss of
mitochondrial membrane potential in the presence of m.14484T>C
would contribute to endothelial dysfunction, which ﬁnally caused im-
paired elasticity and contractility of the aorta [41,45].
One intriguing observation is that half of the maternally-related
members with m.14484T>C presented EH at the time of this study.
The incomplete penetrance of EH suggested a potential inﬂuence of
the nuclear genetic background. Indeed, cells from the asymptomatic
member V:1 had increased ROS and decreased mitochondrial mem-
brane potential (Fig. 5 and Table S7), despite the absence of EH and
young age (28 years old). Further study, with a proper balance of the
different nuclear genetic backgrounds of cases and controls, should becarried out to deﬁne the effect of the nuclear background on clinical ex-
pression of m.14484T>C. In addition, epigenetic modiﬁcations (e.g. gene
methylation, acetylation) to genes involved with adverse vessel remod-
eling, membrane lipid homeostasis and myocardial conduction proper-
ties [46,47] should be closely evaluated in future studies, to identify the
nuclear genes and other molecular modiﬁcations that are actively in-
volved in this process.
In summary, the current report for the presence of m.14484T>C in a
Chinese familywithmaternally inherited EH butwithout LHONprovides
a paradigm for diverse phenotypes of the primary LHON mutation. We
show several lines of evidence that m.14484T>C caused mitochondrial
dysfunction in cells from affectedmembers and thismay be the underly-
ing mechanism for hypertension in this family. Given the absence of an
overt phenotype in some carriers there is a potential complexity that
may also involve mitochondrial genes and other molecular modiﬁca-
tions. Patients with the primary LHONmutation should routinely under-
go cardiac evaluation of aortic compliance and blood pressure. Our study
also provides a new clue for amatrilineal genetic factor of arterial stiffen-
ing and vascular aging. Lifestyle interventionor pharmacotherapy that re-
tards and/or reverses age-related vessel remodeling and stiffness may
represent a potential target for treatment and prevention of maternally
inherited EH.
Conﬂict of interest
None declared.
Acknowledgements
This work was supported by theMinistry of Science and Technology
of China (2011CB910900), the National Natural Science Foundation of
China (30925021), Yunnan Province (2009CI119 and 2011Z044), and
the Chinese Academy of Sciences.
Appendix A. Supplementary data
Supplementary material is available at Journal online. Supple-
mentary data to this article can be found online at http://dx.doi.
org/10.1016/j.bbadis.2012.06.010.
References
[1] J. He, P.K. Whelton, Epidemiology and prevention of hypertension, Med. Clin.
North Am. 81 (1997) 1077–1097.
[2] I. Hajjar, J.M. Kotchen, T.A. Kotchen, Hypertension: trends in prevalence, incidence,
and control, Annu. Rev. Public Health 27 (2006) 465–490.
[3] C.M.M. Lawes, S. Vander Hoorn, A. Rodgers, International Society of Hypertension,
Global burden of blood-pressure-related disease, 2001, Lancet 371 (2008) 1513–1518.
[4] H. Snieder, G.A. Harshﬁeld, F.A. Treiber, Heritability of blood pressure and hemo-
dynamics in African- and European-American youth, Hypertension 41 (2003)
1196–1201.
[5] R.R. Williams, S.C. Hunt, S.J. Hasstedt, P.N. Hopkins, L.L. Wu, T.D. Berry, B.M. Stults,
G.K. Barlow, M.C. Schumacher, R.P. Lifton, J.M. Lalouel, Are there interactions and
relations between genetic and environmental-factors predisposing to high
blood-pressure, Hypertension 18 (1991) 29–37.
[6] Q. Yang, S.K. Kim, F.Z. Sun, J. Cui, M.G. Larson, R.S. Vasan, D. Levy, F. Schwartz, Ma-
ternal inﬂuence on blood pressure suggests involvement of mitochondrial DNA in
the pathogenesis of hypertension: the Framingham Heart Study, J. Hypertens. 25
(2007) 2067–2073.
[7] F.Z. Sun, J. Cui, H. Gavras, F. Schwartz, A novel class of tests for the detection ofmito-
chondrial DNA-mutation involvement in diseases, Am. J. Hum. Genet. 72 (2003)
1515–1526.
[8] A.L. DeStefano, H. Gavras, N. Heard-Costa, M. Bursztyn, A. Manolis, L.A. Farrer, C.T.
Baldwin, I. Gavras, F. Schwartz, Maternal component in the familial aggregation of
hypertension, Clin. Genet. 60 (2001) 13–21.
[9] B. Watson, M.A. Khan, R.A. Desmond, S. Bergman, Mitochondrial DNA mutations
in black Americans with hypertension-associated end-stage renal disease, Am. J.
Kidney Dis. 38 (2001) 529–536.
[10] F. Schwartz, A. Duka, F.Z. Sun, J. Cui, A. Manolis, H. Gavras, Mitochondrial genome
mutations in hypertensive individuals, Am. J. Hypertens. 17 (2004) 629–635.
[11] F.H. Wilson, A. Hariri, A. Farhi, H.Y. Zhao, K.F. Petersen, H.R. Toka, C.
Nelson-Williams, K.M. Raja, C.M. Kashgarian, G.I. Shulman, S.J. Scheinman, R.P.
1543H. Guo et al. / Biochimica et Biophysica Acta 1822 (2012) 1535–1543Lifton, A cluster of metabolic defects caused by mutation in a mitochondrial tRNA,
Science 306 (2004) 1190–1194.
[12] S. Wang, R. Li, A. Fettermann, Z. Li, Y. Qian, Y. Liu, X. Wang, A. Zhou, J.Q. Mo, L. Yang, P.
Jiang, A. Taschner, W. Rossmanith, M.X. Guan, Maternally inherited essential hyper-
tension is associated with the novel 4263A>Gmutation in themitochondrial tRNAIle
gene in a large Han Chinese family, Circ. Res. 108 (2011) 862–870.
[13] H.Y. Zhu, S.W. Wang, L.J. Martin, L. Liu, Y.H. Li, R. Chen, L. Wang, M.L. Zhang, D.W.
Benson, The role of mitochondrial genome in essential hypertension in a Chinese
Han population, Eur. J. Hum. Genet. 17 (2009) 1501–1506.
[14] A.J. Marian, Mitochondrial genetics and human systemic hypertension, Circ. Res.
108 (2011) 784–786.
[15] Y. Goto, I. Nonaka, S. Horai, A mutation in the tRNA(Leu)(UUR) gene associated
with the MELAS subgroup of mitochondrial encephalomyopathies, Nature 348
(1990) 651–653.
[16] J.A. Maassen, G.M. Janssen, L.M. 't Hart, Molecular mechanisms of mitochondrial
diabetes (MIDD), Ann. Med. 37 (2005) 213–221.
[17] H.A. Tuppen, E.L. Blakely, D.M. Turnbull, R.W. Taylor, Mitochondrial DNA muta-
tions and human disease, Biochim. Biophys. Acta 1797 (2010) 113–128.
[18] The sixth report of the Joint National Committee on prevention, detection, evaluation,
and treatment of high blood pressure, Arch. Intern. Med. 157 (1997) 2413–2446.
[19] H.W. Wang, X.Y. Jia, Y.L. Ji, Q.P. Kong, Q.J. Zhang, Y.G. Yao, Y.P. Zhang, Strikingly
different penetrance of LHON in two Chinese families with primary mutation
G11778A is independent of mtDNA haplogroup background and secondary muta-
tion G13708A, Mutat. Res. 643 (2008) 48–53.
[20] Y. Ji, A.M. Zhang, X. Jia, Y.P. Zhang, X. Xiao, S. Li, X. Guo, H.J. Bandelt, Q. Zhang, Y.G. Yao,
Mitochondrial DNA haplogroups M7b1'2 and M8a affect clinical expression of Leber
hereditary optic neuropathy in Chinese families with the m.11778G>A mutation,
Am. J. Hum. Genet. 83 (2008) 760–768.
[21] R.M. Andrews, I. Kubacka, P.F. Chinnery, R.N. Lightowlers, D.M. Turnbull, N. Howell,
Reanalysis and revision of the Cambridge reference sequence for human mitochon-
drial DNA, Nat. Genet. 23 (1999) 147.
[22] J. Gutierrez, S.W. Ballinger, V.M. Darley-Usmar, A. Landar, Free radicals, mito-
chondria, and oxidized lipids: the emerging role in signal transduction in vascular
cells, Circ. Res. 99 (2006) 924–932.
[23] S.W. Ballinger, Mitochondrial dysfunction in cardiovascular disease, Free Radic.
Biol. Med. 38 (2005) 1278–1295.
[24] M.F. O'Rourke, J.A. Staessen, C. Vlachopoulos, D. Duprez, G.E. Plante, Clinical appli-
cations of arterial stiffness; deﬁnitions and reference values, Am. J. Hypertens. 15
(2002) 426–444.
[25] E.G. Lakatta, D. Levy, Arterial and cardiac aging: major shareholders in cardiovas-
cular disease enterprises: Part I: Aging arteries: a “set up” for vascular disease,
Circulation 107 (2003) 139–146.
[26] E.K. Nikoskelainen, M.L. Savontaus, K. Huoponen, K. Antila, J. Hartiala, Pre-excitation
syndrome in Leber's hereditary optic neuropathy, Lancet 344 (1994) 857–858.
[27] Y. Mashima, K. Kigasawa, H. Hasegawa, M. Tani, Y. Oguchi, High incidence of
pre-excitation syndrome in Japanese families with Leber's hereditary optic neu-
ropathy, Clin. Genet. 50 (1996) 535–537.
[28] P. Sorajja, M.G. Sweeney, R. Chalmers, B. Sachdev, P. Syrris, M. Hanna, N.D. Wood,
W.J. McKenna, P.M. Elliott, Cardiac abnormalities in patients with Leber's heredi-
tary optic neuropathy, Heart 89 (2003) 791–792.[29] J. Finsterer, C. Stollberger, C. Prainer, A. Hochwarter, Lone noncompaction in
Leber's hereditary optic neuropathy, Acta Cardiol. 59 (2004) 187–190.
[30] F.C. Rose, A.N. Bowden, P.M. Bowden, The heart in Leber's optic atrophy, Br. J.
Ophthalmol. 54 (1970) 388–393.
[31] A. Nemes, I.F. De Coo, L. Spruijt, H.J. Smeets, P.F. Chinnery, O.I. Soliman, M.L.
Geleijnse, F.J. Ten Cate, Is there alteration in aortic stiffness in Leber hereditary
optic neuropathy? Eur. J. Ophthalmol. 18 (2008) 309–312.
[32] J. Fujitake, H. Mizuta, H. Fujii, Y. Ishikawa, K. Sasamoto, Y. Goto, I. Nonaka, Y.
Tatsuoka, Leber's hereditary optic neuropathy with intracranial arteriovenous
malformation: a case report, Acta Neurol. Belg. 102 (2002) 82–86.
[33] S. Tang, A. Batra, Y. Zhang, E.S. Ebenroth, T. Huang, Left ventricular noncompaction is
associated with mutations in the mitochondrial genome, Mitochondrion 10 (2010)
350–357.
[34] M. Jaksch, S. Hofmann, P. Kaufhold, B. Obermaier-Kusser, S. Zierz, K.D. Gerbitz, A
novel combination of mitochondrial tRNA and ND1 gene mutations in a syn-
drome with MELAS, cardiomyopathy, and diabetes mellitus, Hum. Mutat. 7
(1996) 358–360.
[35] M. van Oven, M. Kayser, Updated comprehensive phylogenetic tree of global
human mitochondrial DNA variation, Hum. Mutat. 30 (2009) E386–E394.
[36] E.K. Nikoskelainen, K. Huoponen, V. Juvonen, T. Lamminen, K. Nummelin, M.L.
Savontaus, Ophthalmologic ﬁndings in Leber hereditary optic neuropathy, with
special reference to mtDNA mutations, Ophthalmology 103 (1996) 504–514.
[37] D. Yu, X. Jia, A.M. Zhang, S. Li, Y. Zou, Q. Zhang, Y.G. Yao, Mitochondrial DNA
sequence variation and haplogroup distribution in Chinese patients with
LHON and m.14484T>C, PLoS One 5 (2010) e13426.
[38] A.M. Zhang, X. Jia, R. Bi, A. Salas, S. Li, X. Xiao, P. Wang, X. Guo, Q.P. Kong, Q. Zhang,
Y.G. Yao, Mitochondrial DNA haplogroup background affects LHON, but not
suspected LHON, in Chinese patients, PLoS One 6 (2011) e27750.
[39] L.I. Rachek, V.I. Grishko, S.P. Ledoux, G.L. Wilson, Role of nitric oxide-induced
mtDNA damage in mitochondrial dysfunction and apoptosis, Free Radic. Biol.
Med. 40 (2006) 754–762.
[40] Y.V. Postnov, S.N. Orlov, Y.Y. Budnikov, A.D. Doroschuk, A.Y. Postnov, Mitochon-
drial energy conversion disturbance with decrease in ATP production as a source
of systemic arterial hypertension, Pathophysiology 14 (2007) 195–204.
[41] Y. Taniyama, K.K. Griendling, Reactive oxygen species in the vasculature: molec-
ular and cellular mechanisms, Hypertension 42 (2003) 1075–1081.
[42] S.W. Ballinger, C. Patterson, C.A. Knight-Lozano, D.L. Burow, C.A. Conklin, Z. Hu, J.
Reuf, C. Horaist, R. Lebovitz, G.C. Hunter, K. McIntyre, M.S. Runge, Mitochondrial
integrity and function in atherogenesis, Circulation 106 (2002) 544–549.
[43] H. Unterluggauer, B. Hampel, W. Zwerschke, P. Jansen-Durr, Senescence-associated
cell death of human endothelial cells: the role of oxidative stress, Exp. Gerontol. 38
(2003) 1149–1160.
[44] G.M. Puddu, E. Cravero, G. Arnone, A. Muscari, P. Puddu, Molecular aspects of
atherogenesis: new insights and unsolved questions, J. Biomed. Sci. 12 (2005)
839–853.
[45] P. Puddu, G.M. Puddu, E. Cravero, S. De Pascalis, A. Muscari, The putative role of mi-
tochondrial dysfunction in hypertension, Clin. Exp. Hypertens. 29 (2007) 427–434.
[46] R.M. Millis, Epigenetics and hypertension, Curr. Hypertens. Rep. 13 (2011) 21–28.
[47] M.P. Turunen, E. Aavik, S. Yla-Herttuala, Epigenetics and atherosclerosis, Biochim.
Biophys. Acta 1790 (2009) 886–891.
